Anti-cancer and heart disease vaccines

9:54:58

2023-04-11

1249

The CEO of Moderna announced that innovative vaccines against diseases such as cancer and the heart disease may be ready for use by the end of the current decade.

Dr. Paul Burton said, in statements to the British newspaper “The Guardian”, that the progress made in “miRNA” technology, which is the technology used to manufacture the “Moderna” company’s pioneering vaccine, has ushered in a golden age of vaccines.

He predicts that by 2030, there will be vaccines for "all kinds" of severe conditions, saving "hundreds of thousands, if not millions of lives," he says.

"We will have these vaccines, they will be very effective, and they will save hundreds of thousands, if not millions of lives," he added.

He continued:

"I think we will be able to offer people all over the world specific cancer vaccines against different types of tumors."

And he continued: “I think what we have learned in recent months is that if you think that the “miRNA” technology is for infectious diseases only, or for the emerging “Corona” virus only, the evidence now is that this is not the case at all, but rather it can be applied to all Types of disease areas, whether cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, and rare diseases.

Burton confirmed that his company, Moderna, "has studies in all of these areas, and they all showed very promising results."

The President of Moderna did not say how the new vaccines would work, but he noted that previous studies showed how miRNAs could be used to fight cancer.

miRNA vaccines work by instructing cells to produce a protein that triggers an immune response against specific pathogens, such as COVID-19.

Scientists claim that these instructions can also be modified to make cells make antigens from the surface of cancer cells, alerting the cancer cells' immune system and launching an attack.

Researchers at the Texas Nano medicine Cancer Center (TCCN) are working to develop Nano vaccines to treat cancer.

In order to vaccinate someone against cancer, doctors first take a biopsy from the person's tumor, then identify the antigen present in the cancer cells, encoding the mRNA vaccine, to trigger the cells to produce the same antigen.

After that, the vaccine is given to the patient, which leads to stimulating his cells to produce the antigen, and to provoke an immune response against it.

Next, the immune cells are trained to destroy any remaining cancer cells in the body, and to hunt down any returning cancer cells.

Doctors confirm that mRNA vaccines can be modified for each patient, to account for different types of cancer and differences between patients, but it is a costly process, according to their weighting.

It is noteworthy that trials of anti-cancer vaccines with mRNA technology are already underway in America and Britain, with results expected to appear in the coming months, which include the cancer vaccine of the company “Moderna”, which was granted by the US Food and Drug Administration the status of “superhero therapy” in a month. last February, paving the way for it to get fast-track approval for use.